Tag Archive for: AmacaThera

Weekly roundup: From awards and appointments to Women in Science Day and the launch of the European Life Sciences Coalition

/in

European Life Sciences Coalition launched to strengthen Europe’s life sciences investment ecosystem The European Life Sciences Coalition (ELSC)  launched this week to strengthen Europe’s life sciences and biotechnology VC ecosystem by mobilising greater levels of private and public investment across the sector. Created in association with Invest Europe, the coalition brings together leading European life […]

Read more

AmacaThera Named Life Sciences Ontario Emerging Company of the Year

/in

Recognition of AmacaThera’s leadership and landmark agreement with Pacira BioSciences for its long‑acting, opioid‑sparing anesthetic in post‑operative pain management Progressing AMT-143 to Phase 2 clinical development in 2026 Toronto, Ontario – February 11, 2026 — AmacaThera, a leading developer of next-generation hydrogel-based drug delivery solutions that enable precise, tunable, and sustained release to improve a […]

Read more

AmacaThera Signs Exclusive Global Licensing Agreement with Pacira BioSciences for Up To US$230 Million, Validating Its Tunable Drug Delivery Platform

/in

AmacaThera receives US$5 million upfront and up to US$225 million in potential future milestone payments with Pacira BioSciences for AMT-143, AmacaThera’s long-acting non-opioid anesthetic for post-operative pain AMT-143 leverages AmacaThera’s breakthrough tunable hydrogel platform, delivering sustained local release of ropivacaine AmacaThera and Pacira will collaborate on the Phase 2 clinical program, and Pacira will fund […]

Read more